High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.

Item

http://www.wikidata.org/entity/Q36469671

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

High-dose CD20-targeted radioi ...... rsistent mantle cell lymphoma.

@ast

High-dose CD20-targeted radioi ...... rsistent mantle cell lymphoma.

@en

type

Item

label

High-dose CD20-targeted radioi ...... rsistent mantle cell lymphoma.

@ast

High-dose CD20-targeted radioi ...... rsistent mantle cell lymphoma.

@en

prefLabel

High-dose CD20-targeted radioi ...... rsistent mantle cell lymphoma.

@ast

High-dose CD20-targeted radioi ...... rsistent mantle cell lymphoma.

@en

P1476

High-dose CD20-targeted radioi ...... rsistent mantle cell lymphoma.

@en

P2093

Andrei R Shustov

http://www.w3.org/2001/XMLSchema#string

Brian G Till

http://www.w3.org/2001/XMLSchema#string

Damian J Green

http://www.w3.org/2001/XMLSchema#string

Edward N Libby

http://www.w3.org/2001/XMLSchema#string

John M Pagel

http://www.w3.org/2001/XMLSchema#string

Johnnie J Orozco

http://www.w3.org/2001/XMLSchema#string

Joseph Rajendran

http://www.w3.org/2001/XMLSchema#string

Leona A Holmberg

http://www.w3.org/2001/XMLSchema#string

Mary Philip

http://www.w3.org/2001/XMLSchema#string

Philip A Stevenson

http://www.w3.org/2001/XMLSchema#string

P2860

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.

Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the

P304

788-797

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.13773

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

171

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26455717

http://www.w3.org/2001/XMLSchema#string

P932

4715476

http://www.w3.org/2001/XMLSchema#string